July brought warm weather and new price hikes for Americans already struggling under unfair list prices.
Medicare spent nearly $2 billion on H.P. Acthar Gel from 2011-2016, according to the agency's data — even though some doctors say an equally effective treatment would have cost a tiny fraction of that amount
My name is April. I live and work in Pensacola, Florida with my wonderful husband and our 11-year-old son. I also have incurable breast cancer.
Receiving assistance from a drug corporation to afford an expensive prescription feels a lot like pharma benevolence. Here's why these programs are robbing us blind:
There is a simple and potentially cost-saving question patients may not know they can ask their pharmacists.
In an attempt to encourage and improve transparency, the FDA released a list of more than 50 drug makers accused by generic drug corporations of stalling providing samples that would increase competition and lower prices.
The problem is the price: 5 reasons the cystic fibrosis community and its allies must band together to speak out about our drug prices – right now.
But I live in fear that we won’t be able to afford his medication from Vertex. I live in fear that stock buybacks and CEO pay raises will come before lowering the price of Eli’s drugs. That’s why I decided to fight back. That’s why I’m calling on all shareholders and the cystic fibrosis community to demand Vertex use its windfall in corporate tax breaks to lower the price of Cystic Fibrosis drugs.